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Editorial
Surgery for refractory mesial temporal lobe 
epilepsy: prognostic factors and early, rather 
than late, intervention
Cirurgia para epilepsia de lobo temporal mesial: fatores prognósticos e intervenção 
precoce melhor que tardia
Carlos Alberto Mantovani Guerreiro
Mesial temporal lobe epilepsy (MTLE) is the most prevalent refractory epilepsy in adolescents and adults, and its pathologic hallmark is classic hippocampal sclerosis. There is the strongest level of evidence (Level A) to indicate surgical treatment for refractory unilateral MTLE1.
The study presented by Jardim et al.2 is important because it confirms the relationship 
between prognostic factors of surgery for unilateral MTLE and the pathologic findings. The 
best postoperative seizure control (i.e. Engel class 1) was associated with classic and severe 
patterns of hippocampal sclerosis (types 1a and 1b, respectively), as well as the presence of an 
initial precipitating injury2. The three patients with normal hippocampal findings were associ-
ated with poor outcome. This point is still controversial in the literature. In general, outcome 
is poorer in patients without hippocampal neuronal cell loss (no hippocampal sclerosis).
Nowadays, modern imaging with resonance techniques offers a very useful and safe way 
to check this point.
The study also reassures in that more than two thirds of the patients became seizure free 
for at least six months, which is considered a short follow-up. This outcome is compatible with 
the literature and it is considered a very successful outcome.
The concept of a medical refractory epilepsy patient is defined as the failure of adequate 
trials of two tolerated, appropriately chosen and used, antiepileptic drug schedules (either as 
monotherapies or in combination) to achieve sustained seizure freedom3. Therefore, it is pos-
sible to make the diagnosis of refractory MTLE relatively quickly.
Unfortunately, patients are operated on after 20 years of seizures, as confirmed by data in 
the article by Jardim et al.2. This astonishing fact occurs not only in Brazil, but also in other or-
ganized countries, such as the USA.
A recent study has shown that early referral for surgery is tremendously advantageous for 
the patients in order to avoid irreversible, disabling social, and psychological consequences of 
recurrent seizures, as well as minimizing the risk of premature death4.
We do hope that our fellow neurologists are aware of this important information and that 
all patients with refractory epilepsy are referred to an epilepsy center to determine if they 
might be candidates for surgery.
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